Glycosylation profile and biological activity of Remicade® compared with Flixabi® and Remsima®.

about

Evaluation of analytical similarity between trastuzumab biosimilar CT-P6 and reference product using statistical analyses.

P2860

Q52684751-CB284EEA-FF3F-4370-8771-CB42FB74778E

P2860

Glycosylation profile and biological activity of Remicade® compared with Flixabi® and Remsima®.

Item

http://www.wikidata.org/entity/Q38699354

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Glycosylation profile and biol ...... ed with Flixabi® and Remsima®.

@en

type

Item

label

Glycosylation profile and biol ...... ed with Flixabi® and Remsima®.

@en

prefLabel

Glycosylation profile and biol ...... ed with Flixabi® and Remsima®.

@en

P1476

Glycosylation profile and biol ...... red with Flixabi® and Remsima®

@en

P2093

Changsoo Lee

http://www.w3.org/2001/XMLSchema#string

JongAh Joanne Lee

http://www.w3.org/2001/XMLSchema#string

Saebom Seo

http://www.w3.org/2001/XMLSchema#string

Sung Chun Cho

http://www.w3.org/2001/XMLSchema#string

Wei Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Fc glycans of therapeutic antibodies as critical quality attributes

Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity.

Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood.

Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism

Physicochemical characterization of Remsima.

Terminal sugars of Fc glycans influence antibody effector functions of IgGs.

The choice of mammalian cell host and possibilities for glycosylation engineering.

IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides.

Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density.

The glycosylation pattern of humanized IgGI antibody (D1.3) expressed in CHO cells.

P304

968-977

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/19420862.2017.1337620

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Min Jeong

Orlando Jaquez

P577

2017-06-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28640663

http://www.w3.org/2001/XMLSchema#string

P921

glycosylation

P932

5540080

http://www.w3.org/2001/XMLSchema#string

Glycosylation profile and biological activity of Remicade® compared with Flixabi® and Remsima®.

about

P2860

P2860

Glycosylation profile and biological activity of Remicade® compared with Flixabi® and Remsima®.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932